AG-221 (Enasidenib)_突变体异柠檬酸脱氢酶2(IDH2)抑制剂_1446502-11-9_Apexbio
Pyridostatin_促生长停滞药物_1085412-37-8_Apexbio
产品名: Pyridostatin 修订日期: 6/30/2016产品说明书化学性质产品名:Pyridostatin Cas No.:1085412-37-8 分子量:596.64 分子式:C31H32N8O5 别名:RR-82;RR82;RR 82 化学名:4-(2-aminoethoxy)-2-N,6-N-bis[4-(2-aminoethoxy)quinolin-2-yl]pyri dine-2,6-dicarboxamide SMILES:C1=CC=C2C(=C1)C(=CC(=N2)NC(=O)C3=CC(=CC(=N3)C(=O)NC4=NC5=CC=CC=C5C(=C4)OCCN)OCCN)OCCN 溶解性:>20.85mg/mL in DMSO 储存条件:Store at -20°C 一般建议: For obtaining a higher solubility , please warm the tube at 37°Cand shake it in the ultrasonic bath for a while.Stock solution can bestored below -20°C for several months.运输条件:Evaluation sample solution : ship with blue iceAll other available size: ship with RT , or blue ice upon request生物活性靶点 :Cell Cycle/Checkpoint 信号通路:G-quadruplex 产品描述:Pyridostatin 是合成的G-四联体小分子稳定剂[1]。
G-四联体是一种DNA 二级结构，通常存在于染色体或端粒的末端。
由于G-四联体也存在于一系列原癌基因（包括c-kit 、K-ras 和Bcl-2）的启动子中，因而被认为参与基因复制和转录的调节过程。
AP20187_二聚体药,具有细胞通透性。_195514-80-8_Apexbio
AP20187 是一种小分子二聚体药物。 为了解决移植物对宿主的抵抗作用，需要对移植细胞的体内行为进行控制。在 conditional
system 中，AP20187 可作为二聚化（CID）的化学诱导剂。在基因治疗中，CIDs 具有很大的 优势，它可以在没有毒性作用的条件下获得选择性。体内研究表明，AP20187 可以显著增加 转导红细胞、血小板以及较小程度上粒细胞的数量。 据报道，AP20187 也被用于 AP20187–LFv2IRE 系统。在该系统中，AP20187 可引起 LFv2IRE 的激活，从而导致肝脏糖原含量和肌肉葡萄糖摄取的增加。
动物实验: 动物模型 剂量 溶解方法
CD1 小鼠
10 mg/kg，腹腔注射。
为了评估 LFv2IRE 的表达和酪氨酸磷酸化，在注射 AP20187 之前 的 4 周，CD1 小鼠经尾静脉注射 AAV2/8-TBG-LFv2IRE 或 AAV2/1-MCK-LFv2IRE 载体。在 AP20187 给药后 2 小时，AP20187 依赖性的 LFv2IRE 酪氨酸磷酸化被检测到，在 6 小时之后达到峰 值，24 小时后回到基础水平。在接受 AAV2/8-TBG-LFv2IRE 而没有
PF-03084014_γ-分泌酶抑制剂_865773-15-5_Apexbio
参考文献: [1]. Li YM, Lai MT, Xu M, Huang Q, DiMuzio-Mower J, Sardana MK, Shi XP, Yin KC, Shafer JA, Gardell SJ. Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl Acad Sci U S A. 2000 May 23;97(11):6138-43. [2]. Wei P, Walls M, Qiu M, et al. Evaluation of selective γ-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Molecular cancer therapeutics, 2010, 9(6): 1618-1628.
参考文献: 1. Wei P, Walls M, Qiu M, et al. Evaluation of selective γ-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Molecular cancer therapeutics, 2010, 9(6): 1618-1628. 2. Arcaroli J J, Quackenbush K S, Purkey A, et al. Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model. British journal of cancer, 2013, 109(3): 667-675. 3. López-Guerra M, Xargay-Torrent S, Rosich L, et al. The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells. Leukemia, 2014. 4. Yabuuchi S, Pai S G, Campbell N R, et al. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer letters, 2013, 335(1): 41-51.
药物Encorafenib(康奈非尼)合成检索总结报告
药物康奈非尼（Encorafenib）合成检索总结报告一、康奈非尼（Encorafenib）简介康奈非尼（Encorafenib）是由时array Biopharma公司研发，于2018年6月在美国上市，主要用于联合Encorafenib对BRAF基因的V600E位点或V600K位点突变的不可切除或转移性黑素瘤患者的治疗。
康奈非尼（Encorafenib）不良反应：疲劳，恶心，呕吐，腹痛和关节痛。
康奈非尼（Encorafenib）分子结构式如下:CAS:1269440-17-6英文名称：Encorafenib中文名称：康奈非尼二、康奈非尼（Encorafenib）合成路线三、康奈非尼（Encorafenib ）合成检索总结报告(一)康奈非尼（Encorafenib ）中间体3的合成合成方法实验步骤参考文献合成方法一Under nitrogen protection,Intermediate compound 1(0.6g,1.7mmol),Intermediate Compound 2(0.23g,1.7mmol),Sodium carbonate (0.71g,6.8mmol)was added in DMSO (20ml)solution,Warming up to 90°C,The reaction was stirred at this temperature for 16h,After the reaction is complete,DCM (30ml ×3)extraction,Combine the organic phase,Dry over anhydrous sodium sulfate,Concentrate for column separation (eluent:Petroleum ether /ethyl acetate (v /v)=1:2),The product 3was obtained in an amount of 0.65g,yield 84%.CN110256408;(2019);(A);CN110256408;(2019);(A)合成方法二A solution of Intermediate 2-chloro-4-(3-iodo-l-isopropyl--lH-pyrazol-4-yl)pyrimidine (1.4g,4.01mmol)1,(S)-methyl l-aminopropan-2-ylcarbamate 2(0.8g,6mmol)and triethylamine (2.8ml,20mmol)in isopropanol (30ml)and dioxane (20mL)was heated in a sealed vessel at 125o C for 48hours.The cooled mixture was concentrated under vacuum,and aqueous sodium bicarbonate was added to the residue.The mixture was extracted with ethyl acetate,and the combined extracts were dried over sodium sulfate,filtered,and concentrated.The crude residue was purified by silica gel columnchromatography (1:2hexanes/ethyl acetate eluant)to provide the title compound 3as a white solid.WO2011/25927;(2011);(A1)English(二)康奈非尼（Encorafenib ）中间体5的合成。
去除丙叉保护
New sialyl Lewis x mimic containing an a -substitutedb 3-amino acid spacerSilvana Pedatella,a,*Mauro De Nisco,a Beat Ernst,b Annalisa Guaragna,aBeatrice Wagner,b Robert J.Woods c and Giovanni Palumbo aa Dipartimento di Chimica Organica e Biochimica,Universita`di Napoli Federico II,Via Cynthia,4I-80126Napoli,Italy bInstitute of Molecular Pharmacy,Pharmacenter,University of Basel,Klingelberstrasse,50CH-4056Basel,Switzerland cComplex Carbohydrate Research Center,University of Georgia,315Riverbend Road,Athens,GA 30602,USAReceived 11June 2007;received in revised form 20August 2007;accepted 2October 2007Available online 7October 2007Abstract—A highly convergent and efficient synthesis of a new sialyl Lewis x (sLe x )mimic,which was predicted by computational studies to fulfil the spacial requirements for a selectin antagonist,has been developed.With a b 2,3-amino acid residue L -galactose (bioisostere of the L -fucose moiety present in the natural sLe x )and succinate are linked,leading to a mimic of sLe x that contains all the required pharmacophores,namely the 3-and 4-hydroxy group of L -fucose,the 4-and 6-hydroxy group of D -galactose and the carboxylic acid of N -acetylneuraminic acid.The key step of the synthesis involves a tandem reaction consisting of a N-deprotection and a suitable O !N intramolecular acyl migration reaction which is promoted by cerium ammonium nitrate (CAN).Finally,the new sialyl Lewis x mimic was biologically evaluated in a competitive binding assay.Ó2007Elsevier Ltd.All rights reserved.Keywords:sLe x ;Selectin antagonist;b 3-Amino acid;Glycomimetic1.IntroductionSelectins 1are involved in the orderly migration of leuco-cytes from blood vessels to the sites of inflammation.2Although extravasation of leucocytes represents an essential defense mechanism against inflammatory stim-uli,excessive infiltration of leucocytes into the surround-ing tissue can cause acute or chronic reactions as observed in reperfusion injuries,stroke,psoriasis,rheu-matoid arthritis,or respiratory diseases.2An early step in this inflammatory cascade is mediated by selectin/carbo-hydrate interactions.Data from both selectin knock out mice 3a–c and LAD type 2patients,3d clearly demon-strate that the selectin–carbohydrate interaction is a pre-requisite for the inflammatory cascade to take place.Since the tetrasaccharide sLe x (1,Fig.1)is the carbo-hydrate epitope recognized by E-selectin,4it became the lead structure for the design of selectin antagonists.5The search for novel selectin antagonist with enhanced adhesion and improved pharmacokinetic properties 5has led to numerous classes of antagonists.In the initial con-tributions,6,7the structure–activity relationship was eluci-dated,revealing the essential pharmacophores which are the carboxylic acid function of N -acetylneuraminic acid,the 3-and 4-hydroxyl group of L -fucose and the 4-and 6-hydroxyl group of D -galactose (highlighted in Fig.1).8In addition,it has been shown that the D -Glc-NAc moiety is not involved in binding.Its principal func-tion is that of a rigid spacer to accommodate the appropriate spacial orientation of L -fucose and D -galact-ose.5For the design of simplified sLe x antagonists 5a dual strategy was pursued by (1)eliminating monosaccharide moieties by non-carbohydrate linkers,and (2)substitut-ing metabolically labile O-glycosidic bonds.Considering the glycoaminoacid mimics reported by Wong,9which exhibit remarkable pharmacological0008-6215/$-see front matter Ó2007Elsevier Ltd.All rights reserved.doi:10.1016/j.carres.2007.10.001*Corresponding author.Tel.:+39081674118;fax:+39081674119;e-mail:pedatell@unina.itAvailable online at Carbohydrate Research 343(2008)31–38activity,we report herein the synthesis and the biological evaluation of the scaffold 2,a member of a new family of antagonists based on a dihydroxylated b -amino acid as a substitute of galactose.This scaffold is decorated with a suitably modified L -fucose and a carboxylic acid moiety mimicking the native N -acetylneuraminic acid.The corresponding target molecule 2(Fig.1)therefore contains (2S ,3S )-2-hydroxy-b 3-serine which is coupled with the free amino group of 6-amino-6-deoxy-L -galact-ose (L -Fuc replacement)and,at the other end,with a succinic acid (D -NeuNAc replacement).An important factor for affinity is the spacial orientation of the phar-macophores in the bioactive conformation.5d,e This is expected to be realized with the rigid diamide core.2.Results and discussionA conformational analysis of 2by molecular dynamic studies indicated that the low energy conformer-2pre-sented in Figure 1exhibits distances between the carbox-ylate and C-1and C-2of L -galactose (9.2and 9.1A˚,respectively),which are similar to the one found in the bioactive conformation 10of sLe x .Conformer-2is only less stable by 5.29kJ/mol compared to its lowest energy conformation and is characterized by differing flexibili-ties of the dihedral angles h ,u and x (Fig.2).Whereas h and u show considerable flexibility over the 10,000ps period of the MD simulation,x is rather stiff,leading to a partial preorganization of 2in the bioactive conformation.The synthesis started with the preparation of 6-amino-6-deoxy-L -galactose derivative 4from commercially available L -galactose according to a known procedure 11(Scheme 1).According to this procedure,the acetona-tion to achieve 1,2:3,4-di-O -isopropyliden-L -galactose(3),using CuSO 4/H 2SO 4in acetone,gave only poor yields (55%).Using an improved procedure 12(polystyryl diphenyl phosphine–iodine complex,prepared in situ,in anhy-drous acetone,at rt under nitrogen)3was obtained in 95%yield.Tosylation of the primary hydroxy group fol-lowed by substitution with sodium azide and catalytic hydrogenation (Pd/H 2)afforded the free amine 4in 69%overall yield from L -galactose.(2S ,3S )-2-Hydroxy-b 3-serine methyl ester derivative 7,was obtained diastereoselectively 13from commercially available O -benzyl-L -serine via enolate formation (by KHMDS)of the corresponding fully protected b 3-serine 5and the coupling of the enolate with racemic 2-[(4-methylphenyl)sulfonyl]-3-phenyloxaziridine (6)(Scheme 2).The hydrolysis of methyl ester 7afforded 8in excellent yield without any traces of racemization.Then,the 2-hydroxy-b 3-amino acid 8was coupled with the previously prepared 6-amino-L -galactose deriv-ative 4by treatment with DCC and HOBT in CH 2Cl 2,yielding 9in good yield (75%)(Scheme 3).The last step of the synthesis was the introduction of a carboxylate side chain at the N-terminus of 9.The first attempt to remove the 4-methoxybenzyl ether protection (PMB)with cerium ammonium nitrate (CAN)14was accompanied by the formation of several byproducts due to the cleavage of C-2–C-3bond of the b -aminoac-idic moiety.To avoid a possible interference of the free hydroxyl group with CAN,compound 9was first acetyl-ated and then treated with CAN.A single product was formed,which turned out not to be the desired N-depro-tected derivative,but the product of a subsequent O !N intramolecular acetyl migration.15When this O !N intramolecular acyl migration was applied to ester 10,which was obtained byesterificationFigure 1.Identical spacial orientation of the pharmacophores in sLe x (1)and the glycoaminoacid mimic 2.32S.Pedatella et al./Carbohydrate Research 343(2008)31–38of 9with 3-carbomethoxypropionyl chloride,product 11could be isolated in excellent 90%yield (Scheme 3).Finally,the removal of the protecting groups by hydrogenolysis on Pd/C in an ultrasound bath (!12),followed by alkaline hydrolysis (!13),and acidic hydrolysis (TFA/H 2O)of the isopropylidene groups (Scheme 3)yielded 2as an anomeric mixture (a /b =1:2).3.Biological evaluationVarious formats of cell-free competitive binding assays under static conditions have been reported.16–18We used microtiter plates coated with human recombinant E-selectin/IgG or P-selectin/IgG,which were incubated with 2and commercially available sLe x/biotin-polyacry-Figure 2.The plots A,B,and C show the fluctuations of the h ,u ,and x torsional angles in compound 2monitored during the 10,000ps MD simulation in a box of TIP3P water molecules;A,B:the h and u dihedral angles are highly variable within the MD simulation time frame;C:the x torsion angle remains practically unchanged during the MD simulation.S.Pedatella et al./Carbohydrate Research 343(2008)31–3833late.After unbound ligand and polymer were washed from the plate,streptavidin/horseradish peroxidase con-jugate was added to enable colorimetric determination of binding.18b As a reference compound,sialyl Lewis x with an IC50value of0.9mM for E-selectin and P3mM for P-selectin was used.With2,a moderate inhibition of the interaction of sLe x/E-selectin (IC50P6mM)could be detected.However,the interac-tion of P-selectin with the sLe x-polyacrylate polymer could not be inhibited with2(see Table1).4.ConclusionThe new sLe x mimic2was designed and synthesized starting from an L-galactose derivative4and orthogo-nally protected(2S,3S)-2-hydroxy-b3-serine8in six steps.Our synthesis features the use of cerium ammo-nium nitrate(CAN)to perform a useful O!N intra-molecular acyl migration reaction on the succinoyl ester10.However,biological testing revealed that this sLe x mimic shows only low affinity of E-selectin(IC50=6mM)and no activity(IC50>10mM)forP-selectin,respectively.Since the spatially correct arrangement of the phar-macophores can be realized in2,the low affinity can alsobe due to the considerable conformationalflexibility ofthe dihedral angles h and u(Fig.2A and B)leading tosubstantial cost of entropy upon binding.5.Experimental5.1.General methodsTriphenyl phosphine polymer-bound was purchasedfrom Fluka Chemical Co.All moisture-sensitive reac-tions were performed under a nitrogen atmosphere usingoven-dried glassware.Solvents were dried over standarddrying agents and freshly distilled prior to use.Reac-tions were monitored by TLC(precoated silica gel plateF254,Merck).Column chromatography:Merck Kiesel-gel60(70–230mesh);flash chromatography:MerckKieselgel60(230–400mesh).Optical rotations weremeasured at25±2°C in the stated solvent.1H and 13C NMR spectra were recorded on NMR spectro-meters operating at400or500MHz and50,100or125MHz,respectively.Wherever necessary,two-dimen-Table1.Biological evaluation dataTest compound E-Selectin(mM)P-Selectin(mM)Sialyl Lewis x(1)0.9P3Glycoaminoacid(2)P6>1034S.Pedatella et al./Carbohydrate Research343(2008)31–38sional1H–1H COSY experiments were carried out for complete signal bustion analyses were performed using CHNS analyzer.5.2.1,2:3,4-Di-O-isopropylidene-a-L-galactopyranose(3) To a magnetically stirred suspension of dry polystyryl diphenyl phosphine(1.12g,%3.34phosphine units)in anhydrous acetone(10mL)at rt,a solution of I2 (0.85g,3.34mmol)in the same solvent(30mL)was added dropwise in the dark and under dry nitrogen atmosphere.After15min,solid L-galactopyranose (0.33g,1.67mmol)was added in one portion to the sus-pension.TLC monitoring(CHCl3/CH3OH,9:1)showed that the starting sugar was completely consumed within 30min.The reaction mixture was thenfiltered through a glass sinter funnel and washed with acetone.The solvent was removed under reduced pressure and the solid resi-due recrystallized from CHCl3/hexane(1:2)to give thefinal product3(0.41g,95%yield);½a 25D À59.5(c1.5,CHCl3),lit.19½a 25D À55.0(c3.6,CHCl3).1H and13CNMR spectral data matched that reported.125.3.6-Amino-6-deoxy-1,2:3,4-di-O-isopropylidene-a-L-galactopyranose(4)The title compound was prepared following May’s pro-cedure11starting from3.5.4.(2S,3S)-4-(Benzyloxy)-3-[di(4-methoxybenzyl)-amino]-2-hydroxybutanoic acid(8)To a stirring solution of7,prepared as already re-ported,13(1.04g, 2.00mmol)in MeOH(13mL)was added dropwise aq NaOH(1.0M solution in H2O, 4.0mL)at0°C.The reaction,allowed to warm to rt, was stirred for6.5h and then it was diluted with EtOAc (100mL).The organic phase was treated with a solution of HCl(3M,2·100mL),washed with brine(50mL) and dried over Na2SO4.The solvent was removed under reduced pressure and the residue was purified byflash chromatography(CHCl3/MeOH,9:1)to afford8(0.90g,92%)as a pale yellow oil.½a 25D +44.0(c0.9,CHCl3);1H NMR(500MHz,CDCl3):d 3.45(ddd, 1H,J3,211.0,J3,4a9.6,J3,4b3.4Hz,H-3),3.82(s,6H, 2·OCH3), 3.84(d,1H,J2,311.0Hz,H-2), 3.89(d, 2H,J a,b12.0Hz,2·CH a PMB),3.98(dd,1H,J4a,4b 11.3,J4a,39.6Hz,H a-4),4.10(dd,1H,J4b,4a11.3,J4b,33.4Hz,H b-4),4.22(d,2H,J b,a12.0Hz,2·CH b PMB),4.59(d,1H,J a,b11.7Hz,CH a Ph),4.73(d,1H,J b,a 11.7Hz,CH b Ph), 6.89(d,4H,J ortho8.8Hz,ArH), 7.25(d,4H,J ortho8.8Hz,ArH),7.38–7.48(m,5H, PhH);13C NMR(125MHz,CDCl3)d54.2,55.1,60.1, 64.1,66.2,73.9,114.6,128.1,128.6,131.6,136.9, 160.2,175.0.Anal.Calcd for C27H31NO6:C,69.66;H, 6.71;N,3.01.Found:C,69.42;H,6.69;N,3.03.5.5.N1-(1,2:3,4-Di-O-isopropylidene-6-deoxy-a-L-galac-topyranos-6-yl)-(2S,3S)-4-(benzyloxy)-3-[di(4-methoxy-benzyl)amino]-2-hydroxybutanamide(9)HOBT(0.35g,2.58mmol)was added to a stirred solu-tion of b2,3-amino acid8(0.60g,1.29mmol)in anhy-drous CH2Cl2(10mL)at rt.After30min,to the resulting mixture a solution of compound4(0.30g, 1.17mmol)and DCC(0.40g,1.42mmol)in the same solvent(10mL)was added dropwise over5min at 0°C.The solution was allowed to warm slowly to rt and,after15h,most of the solvent was evaporated under reduced pressure and replaced by EtOAc.The precipitate wasfiltered and the solution was washed with saturated NaHCO3solution,brine until neutral, then dried(Na2SO4),and concentrated under reduced pressure.Chromatography of the crude residue on silica gel(hexane/EtOAc,1:1)afforded the oily coupling prod-uct9(0.62g,75%).½a 25D+8.5(c0.9,CHCl3);1H NMR (500MHz,CDCl3)d1.31,1.32,1.43,1.45(4s,12H, 4·CH3), 3.24(ddd,1H,J60a;60b13:9;J60a;508:1; J60a;NH4:4Hz,H a-60), 3.36–3.43(m,1H,H-3), 3.51 (ddd,1H,J60b;60a13:9;J60b;506:8;J60b;NH4:9Hz,H b-60), 3.67(d,2H,J a,b13.2Hz,2·CH a PMB),3.73(d,2H, J b,a13.2Hz,2·CH b PMB), 3.79(s,6H,2·OCH3),3.80–3.85(m,1H,H-50),3.92(dd,1H,J4a,4b10.7,J4a,34.4Hz,H a-4), 3.95–4.08(m,3H,H-40,H-2,H b-4), 4.27(dd,1H,J20;104:9;J20;301:9Hz,H-20), 4.50(dd, 1H,J30;407:8;J30;201:9Hz,H-30), 4.55(d,1H,J a,b 11.7Hz,CH a Ph),4.58(d,1H,J b,a11.7Hz,CH b Ph),5.48(d,1H,J10;204:9Hz,H-10),6.84(d,4H, J ortho8.3Hz,ArH),7.18(d,4H,J ortho8.3Hz,ArH), 7.28–7.40(m,5H,PhH),7.50–7.58(m,1H,NH);13C NMR(125MHz,CDCl3)d22.9,24.7,25.2,26.2,39.7, 54.7,55.5,59.5,66.3,68.4,69.6,70.7,71.0,71.7,73.7, 96.5,108.9,109.6,114.1,127.9,128.7,130.6,131.1, 138.1,159.0,173.8.Anal.Calcd for C39H50N2O10:C, 66.27;H,7.13;N,3.96.Found:C,66.50;H,7.11;N, 3.93.5.6.1-{[(1S,2S)-3-(Benzyloxy)-2-[di(4-methoxybenzyl)-amino]-1-[(1,2:3,4-di-O-isopropylidene-6-deoxy-a-L-galactopyranos-6-yl)carbamoyl]propyl}4-methyl succi-nate(10)3-Carbomethoxy propionyl chloride(0.17g,1.16mmol) and anhydrous pyridine(94l L,1.16mmol)were added to a solution of compound9in anhydrous CH2Cl2 (11mL)at0°C.The stirring solution was allowed to warm slowly to rt and after4h most of the solvent was evaporated under reduced pressure and replaced by EtOAc.The organic phase was washed with brine (2·30mL),dried(Na2SO4),and concentrated under re-duced pressure.The residue oil was purified by silica gel chromatography(hexane/EtOAc,8:2!6:4)to give theoily product10(0.56g,90%).½a 25D+18.0(c0.8,CHCl3);S.Pedatella et al./Carbohydrate Research343(2008)31–38351H NMR(500MHz,CDCl3)d1.29,1.32,1.43,1.45(4s, 12H,4·CH3),2.58–2.68(m,4H,CH2–CH2),3.05(ddd, 1H,J60a;60b13:9;J60a;508:8;J60a;NH3:5Hz,H a-60),3.51–3.56(m,1H,H-2), 3.60(d,2H,J a,b13.1Hz, 2·CH a PMB),3.65(d,2H,J b,a13.1Hz,2·CH b PMB), 3.66(s,3H,CH3OCO),3.67–3.80(m,10H,H b-60,H-50, 2·OCH3,2·H-3),4.13(dd,1H,J40;307:8;J40;501:6Hz, H-40),4.27(dd,1H,J20;104:9;J20;302:5Hz,H-20),4.44 (s,2H,CH2Ph), 4.56(dd,1H,J30;407:8;J30;202:5Hz, H-30),5.46(d,1H,J10;204:9Hz,H-10),5.51(d,1H,J1,2 4.3Hz,H-1),6.54(dd,1H,J NH;60b8:0;J NH;60a3:5Hz, NH),6.82(d,4H,J ortho8.7Hz,ArH),7.27(d,4H,J ortho 8.7Hz,ArH),7.30–7.39(m,5H,PhH);13C NMR (100MHz,CDCl3)d24.8,25.4,26.1,26.4,29.2, 29.6,39.6,52.2,54.4,55.6,58.3,67.2,67.8,71.0, 71.2,71.9,72.9,73.3,96.6,109.2,109.8,114.0, 127.9,128.1,128.7,130.5,132.1,138.7,159.0, 169.4,171.1,173.1.Anal.Calcd for C44H56N2O13:C, 64.38;H,6.88;N,3.41.Found:C,64.19;H,6.85;N, 3.43.5.7.Methyl3-{[(1S,2S)-1-[(benzyloxy)methyl]-2-hydroxy-2-([1,2:3,4-di-O-isopropylidene-6-deoxy-a-L-galactopyranos-6-yl]carbamoyl)ethyl]carbamoyl}pro-panoate(11)A solution of CAN(4.9mL,2.9mmol)in H2O was added to a stirring solution of compound10(0.48g, 0.58mmol)in MeCN at0°C.The reaction was kept to0°C for1h and then was allowed to warm to rt.After 18h,the reaction mixture was quenched by the addition of a saturated NaHCO3solution(50mL)and extracted with CHCl3.The organic layer was washed with brine until neutral,dried(Na2SO4),and concentrated under reduced pressure.The residue,after chromatography on silica gel(CHCl3/MeOH,95:5),gave the oily product11(0.20g,90%).½a 25D À11.0(c0.6,CHCl3);1H NMR(500MHz,CDCl3)d1.31,1.33,1.45,1.47(4s,12H, 4·CH3),2.50(t,2H,J1,26.8Hz,CH2–CH2),2.65(t, 2H,J2,1 6.8Hz,CH2–CH2), 3.28(ddd,1H, J60a;60b13:9;J60a;508:8;J60a;NH4:0Hz,H a-60),3.61–3.68 (m,5H,H b-60,CH a PMB,CH3OCO), 3.84–3.90 (m,2H,H-50,CH b PMB), 4.16(dd,1H, J40;307:9;J40;501:8Hz,H-40),4.23(br s,1H,H-1),4.30 (dd,1H,J20;104:9;J20;302:4Hz,H-20), 4.35–4.40(m, 1H,H-2), 4.48(d,1H,J a,b11.7Hz,CH a Ph), 4.52 (d,1H,J b,a11.7Hz,CH b Ph), 4.59(dd,1H, J30;407:9;J30;202:4Hz,H-30),5.51(d,1H,J10;204:9Hz, H-10),6.31(br d,1H,J NH,16.8Hz,NH serine),7.22–7.26(m,1H,NH galactosamine),7.30–7.40(m,5H,PhH); 13C NMR(100MHz,CDCl3)d24.8,25.3,26.3,26.4, 29.6,31.2,40.0,52.2,53.7,66.6,69.7,70.9,71.2,72.1, 73.5,96.7,109.1,109.9,128.2,128.4,128.9,137.8, 171.9,173.3,173.6.Anal.Calcd for C28H40N2O11:C, 57.92;H,6.94;N,4.82.Found:C,58.14;H,6.91;N, 4.84.5.8.Methyl3-{[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-([1,2:3,4-di-O-isopropylidene-6-deoxy-a-L-galactopyr-anos-6-yl]carbamoyl)ethyl]carbamoyl}propanoate(12)A solution of compound11(0.20g,0.35mmol)in MeOH(4mL)was added to a stirring suspension of 5%palladium on carbon(0.07g)in the same solvent (5mL)and then was hydrogenated(1atm)at40°C. Theflask was immersed in an ultrasound cleaning bath filled with water and sonicated for22h.Then the sus-pension wasfiltered through CeliteÒand the solid washed twice with MeOH(2·5mL).The organic phase was evaporated down under reduced pressure to afford the oily product12(0.16g,93%).½a 25D+0.4(c0.5, CHCl3);1H NMR(500MHz,CDCl3)d 1.33, 1.36, 1.47,1.49(4s,12H,4·CH3),2.51–2.57(m,2H,CH2–CH2), 2.63–2.69(m,2H,CH2–CH2), 3.37(ddd,1H, J60a;60b13:4;J60a;508:3;J60a;NH4:4Hz,H a-60),3.65–3.72 (m,4H,H b-60,CH3OCO), 3.74(dd,1H,J Ha,Hb 11.9,J Ha,1 4.9Hz,CH a OH), 3.87(ddd,1H, J50;60a8:3;J50;60b3:9;J50;401:9Hz,H-50),4.05(dd,1H, J Hb,Ha11.9,J Hb,11.5Hz,CH b OH),4.15–4.18(m,1H, H-1),4.19(dd,1H,J40;307:8;J40;501:9Hz,H-40),4.27–4.30(m,1H,H-2),4.31(dd,1H,J20;104:9;J20;302:4Hz, H-20),4.61(dd,1H,J30;407:8;J30;202:4Hz,H-30),5.20 (br s,1H,OH),5.50(d,1H,J10;204:9Hz,H-10),5.90 (br s,1H,OH),6.77(d,1H,J NH,16.3Hz,NH serine), 7.54–7.64(m,1H,NH galactosamine);13C NMR (50MHz,CDCl3)d22.7,23.2,24.3,27.4,28.0,28.7, 38.1,50.2,54.0,60.5,64.4,68.8,69.1,70.1,75.5,94.6, 107.1,107.9,171.6,173.2,173.4.Anal.Calcd for C21H34N2O11:C,51.42;H,6.99;N,5.71.Found:C, 51.28;H,6.96;N,5.73.5.9.3-{[(1S,2S)-2-Hydroxy-1-(hydroxymethyl)-2-([1,2:3,4-di-O-isopropylidene-6-deoxy-a-L-galactopyr-anos-6-yl]carbamoyl)ethyl]carbamoyl}propanoic acid(13) One molar solution of aq NaOH(0.78mL,0.78mmol) was added to a stirring solution of compound12 (0.13g,0.26mmol)in MeOH(13mL)at0°C.The reac-tion mixture was allowed to warm slowly to rt and after 3h(TLC monitoring;CHCl3/CH3OH,8:2)was quenched with some drops of acetic acid until neutral. The precipitate wasfiltered and the organic phase was evaporated under reduced pressure to afford the oilyproduct13(0.11g,91%).½a 25D+9.0(c0.8,CH3OH); 1H NMR(400MHz,CD3OD)d1.33,1.36,1.43,1.47 (4s,12H,4·CH3), 2.40–2.52(m,4H,CH2–CH2), 3.35(dd,1H,J60a;60b14:0;J60a;508:1Hz,H a-60), 3.48 (dd,1H,J60b;60a14:0;J60b;504:4Hz,H b-60), 3.61–3.66 (m,2H,CH2OH),3.94–3.99(m,1H,H-50),4.20(br d,1H,J2,1 3.7Hz,H-2), 4.24–4.31(m,2H,H-40, H-1),4.34(dd,1H,J20;105:0;J20;302:5Hz,H-20),4.63 (dd,1H,J30;408:0;J30;202:5Hz,H-30), 5.48(d,1H, J10;205:0Hz,H-10);13C NMR(125MHz,CD3OD)36S.Pedatella et al./Carbohydrate Research343(2008)31–38d23.2,24.5,25.1,26.3,34.0,34.6,40.7,55.3,61.1,67.4,71.9,72.2,72.9,73.2,97.8,109.9,110.5,174.7,176.3,181.0.Anal.Calcd for C20H32N2O11:C,50.42;H,6.77;N,5.88.Found:C,50.28;H,6.79;N,5.89.5.10.3-{[(1S,2S)-2-Hydroxy-1-(hydroxymethyl)-2-([6-deoxy-L-galactopyranos-6-yl]carbamoyl)ethyl]carbam-oyl}propanoic acid(2)A solution of glycoaminoacid13(0.11g,0.23mmol)inTFA/H2O(9:1,5mL)was stirred at rt.After3h,thereaction solvent was evaporated under reduced pressureto afford a crude that was purified by Sephadex G-10column leading to the mimic2as a mixture of b and aanomers in2:1ratio(0.067g,80%).1H NMR(500MHz,D2O)d 2.33–2.41(m,4H,CH2–CH2),3.30–3.38(m,2.66H,H-20b,2·H-60b,2·H-60a),3.52(dd,0.66H,J30;2010:0;J30;403:3Hz,H-30b), 3.53–3.60 (m,2H,CH2OH), 3.63(br dd,0.66H,J50;60a7:4;J50;60b5:0Hz,H-50b), 3.68(dd,0.34H,J20;3010:3; J20;103:6Hz,H-20a), 3.72(br dd,0.34H,J30;2010:3; J30;403:1Hz,H-30a), 3.76(br d,0.66H,J40;303:3Hz, H-40b),3.82(br d,0.34H,J40;303:1Hz,H-40a),3.96–4.02(m,0.34H,H-50a),4.11–4.23(m,2H,H-1,H-2),4.43(d,0.66H,J10;207:8Hz,H-10b),5.12(d,0.34H, J10;203:6Hz,H-10a);13C NMR(125MHz,D2O)d 31.5,32.5,41.7(C-60b),41.8(C-60a),55.7(C-2),61.8(CH2OH),70.5(C-20a,C-50a),71.3(C-30a),71.4(C-40b),71.8(C-40a),73.6(C-1),74.1(C-20b),74.9(C-30b,C-50b),94.6(C-10a),98.8(C-10b).Anal.Calcd forC14H24N2O11:C,42.43;H,6.10;N,7.07.Found:C,42.30;H,6.09;N,7.09.putational methodsMolecular dynamics simulations were performed usingthe AMBER7.0suite programs20using the SANDER mod-ule.The simulated structure2was built up by module XLEAP of AMBER using the AMBER forcefield PARM99.21 The GLYCAM2000parameters22,23were implemented forthe oligosaccharide simulations.The charges were takenfrom ab initio calculations performed by GAUSSIAN98molecular modelling package,24using the Hartree–Fockmethod with6-31G*basic set.The MD simulation of2were performed with a time step of1fs in a cubic box ofwater8.0A˚to the side containing1102TIP3P watermolecules.25After heating and equilibration for50psthe simulations were performed for10ns,under periodicboundary conditions,at constant pressure(1atm),andconstant temperature(300K).Energy minimizationsand MD simulations were performed with a dielectricconstant of unity,and a cut-offvalue for non-bondedinteractions of8A˚.The1–4electrostatic and van derWaals interactions were scaled by the standard values(SCEE=1.2,SCNB=2.0).Post-processing of the trajectories(torsional,distance and energy analysis)was performed using the CARNAL module of AMBER7.0package.AcknowledgementsS.P.is grateful to Professor Steve Hanessian,who intro-duced her to the fascinating sLe x researchfield.We thank Oto Miedico for collecting valuable results while performing his master thesis work and Professor Romu-aldo Caputo for useful discussions.We are grateful to Dr Cristina de Castro for her help in the purification protocol of thefinal product.1H and13C NMR spectra were performed at Centro Interdipartimentale di Met-odologie Chimico-Fisiche(CIMCF),Universita‘di Na-poli Federico II.Varian Inova500MHz spectrometer is the property of Naples Laboratory of Consorzio Inter-universitario Nazionale La Chimica per l’Ambiente (INCA).References1.Kansas,G.S.Blood1996,88,3259–3287.2.(a)Lobb,R.R.In Adhesion.Its Role in InflammatoryDisease;Harlan,J.M.,Liu,D.Y.,Eds.;Freeman,W.H.: New York,1992,Chapter1,pp1–18;(b)Paulson,J.C.In Adhesion.It’s Role in Inflammatory Disease;Harlan,J.M., Liu, D.Y.,Eds.;Freeman,W.H.:New York,1992, Chapter2,pp19–42;(c)Varki,A.Proc.Natl.Acad.Sci.U.S.A.1994,91,7390–7397.3.(a)Tedder,T.F.;Steeber,D.A.;Chen,A.;Engel,P.FASEB J.1995,9,866–873;(b)McEver,R.;Moore,K.;Cummings,R.D.J.Biol.Chem.1995,270,11025–11028;(c)Lasky,L.Annu.Rev.Biochem.1995,64,113–139;(d)von Adrian,U.H.;Berger, E.M.;Ramezani,L.;Chambers,J.D.;Ochs,H.D.;Harlan,J.M.;Paulson,J.C.;Etzioni,A.;Arfors,K.-E.J.Clin.Invest.1993,91,2893–2897.4.(a)Phillips,M.;Nudelman,E.;Gaeta,F.C.;Perez,M.;Singhal,A.K.;Hakomori,S.-L.;Paulson,J.C.Science 1990,250,1130–1132;(b)Walz,G.;Aruffo,A.;Kolanus, W.;Bevilacqua,M.;Seed,B.Science1990,250,1132–1135;(c)Berg,E.L.;Robinson,M.K.;Mansson,O.;Butcher,E.C.;Magnani,J.L.J.Biol.Chem.1991,266, 14869–14872.5.For reviews see:(a)Ernst,B.;Kolb,H.C.;Schwardt,O.In The Organic Chemistry of Sugars;Levy,D.E.,Fu¨gedi, P.,Eds.;Taylor&Francis Group,2006;pp803–861;(b) Kaila,N.;Thomas,B.E.,IV Med.Res.Rev.2002,22, 566–601;(c)Simanek,E.E.;McGarvey,G.J.;Jablonow-ski,J.A.;Wong,C.-H.Chem.Rev.1998,98,833–862;(d) Kolb,H.C.;Ernst,B.Chem.Eur.J.1997,3,1571–1578;(e)Kolb,H.C.;Ernst,B.Pure Appl.Chem.1997,69,1879–1884;(f)Bertozzi,C.R.Chem.Biol.1995,2,703–708;(g)Musser,J.H.;Anderson,M.B.;Levy,D.E.Curr.Pharm.Des.1995,1,221–232;(h)Giannis,A.Angew.Chem.,Int.Ed.Engl.1994,33,178–180.6.Brandley, B.K.;Kiso,M.;Abbas,S.;Nikrad,P.;Srivasatava,O.;Foxall, C.;Oda,Y.;Hasegawa, A.Glycobiology1993,3,633–641.S.Pedatella et al./Carbohydrate Research343(2008)31–38377.Ramphal,J.Y.;Zheng,Z.-L.;Perez,C.;Walker,L.E.;DeFrees,S.A.;Gaeta,F.C.A.J.Med.Chem.1994,37, 3459–3463,and literatures cited herein.8.(a)Stahl,W.;Sprengard,U.;Kretschmar,G.;Kunz,H.Angew.Chem.,Int.Ed.Engl.1994,33,2096–2098;(b) Somers,W.S.;Tang,J.;Shaw,G.D.;Camphausen,R.T.Cell2000,103,467–479.9.Cappi,M.W.;Moree,W.J.;Qiao,L.;Marron,T.G.;Weitz-Schmidt,G.;Wong, C.-H.Bioorg.Med.Chem.1997,5,283–296.10.(a)Scheffler,K.;Ernst,B.;Katopodis,A.;Magnani,J.L.;Wang,W.T.;Weisemann,R.;Peters,T.Angew.Chem., Int.Ed.Engl.1995,34,1841–1844;(b)Scheffler,K.;Brisson,J.-R.;Weisemann,R.;Magnani,J.L.;Wong,W.T.;Ernst,B.;Peters,T.J.Biomol.NMR1997,9,423–436.11.May,J.A.,Jr.;Sartorelli,J.J.Med.Chem.1979,22,971–976.12.Pedatella,S.;Guaragna,A.;D’Alonzo,D.;De Nisco,M.;Palumbo,G.Synthesis2006,2,305–308.13.Caputo,R.;Cecere,G.;Guaragna, A.;Palumbo,G.;Pedatella,.Chem.2002,17,3050–3054.14.Reetz,M.T.;Ro¨hrig,D.Angew.Chem.,Int.Ed.Engl.1989,28,1706–1709.15.Sohma,Y.;Hayashi,Y.;Skwarczynski,M.;Hamada,Y.;Sasaki,M.;Kimura,T.;Kiso,Y.Biopolymers(Peptide Sci.)2004,76,344–356.16.Rao,B.N.;Anderson,M.B.;Musser,J.H.;Gilbert,J.H.;Schaefer,M.E.;Foxall,C.;Brandley,B.K.J.Biol.Chem.1994,269,19663–19666.17.(a)Foxall,C.;Watson,S.R.;Dowbenko,D.;Fennie,C.;Lasky,L.A.;Kiso,M.;Hasegawa,A.;Asa,D.;Brandley,B.K.J.Cell.Biol.1992,117,895–902;(b)Jacob,G.S.;Kirmaier,C.;Abbas,S.Z.;Howard,S.C.;Steininger,C.N.;Welply,J.K.;Scudder,P.Biochemistry1995,34, 1210–1217;(c)Galustian,C.;Childs,R.A.;Yuen,C.-T.;Hasegawa,A.;Kiso,M.;Lubineau,A.;Shaw,G.;Feizi,T.Biochemistry1997,36,5260–5266;(d)Marinier, A.;Martel, A.;Banville,J.;Bachand, C.;Remillard,R.;Lapointe,P.;Turmel,B.;Menard,M.;Harte,W.E.,Jr.;Wright,J.J.K.;Todderud,G.;Tramposch,K.M.;Bajorath,J.;Hollenbaugh,D.;Aruffo,A.J.Med.Chem.1997,40,3234–3237.18.(a)Weitz-Schmidt,G.;Stokmaier,D.;Scheel,G.;Nifan-t’ev,N.E.;Tuzikov,A.B.;Bovin,N.V.Anal.Biochem.1996,238,184–190;(b)Thoma,G.;Magnani,J.L.;O¨hrlein,R.;Ernst,B.;Schwarzenbach,F.;Duthaler,R.O.J.Am.Chem.Soc.1997,119,7414–7415.19.Schmidt,O.T.Meth.Carbohydr.Chem.1969,1140–1142.20.Case,D.A.;Pearlman,D.A.;Caldwell,J.W.;Cheatham,T. E.,III;Wang,J.;Ross,W.S.;Simmerling, C.L.;Darden,T.A.;Merz,K.M.;Stanton,R.V.;Cheng,A.L.;Vincent,J.J.;Crowley,M.;Tsui,V.;Gohlke,H.;Radmer, R.J.;Duan,Y.;Pitera,J.;Massova,I.;Seibel,G.L.;Singh,U.C.;Weiner,P.K.;Kollman,P.A.AMBER7;University of California:San Francisco,2002.21.Cornell,W.D.;Cieplak,P.;Bayly,C.I.;Gould,I.R.;Merz,K.M.;Ferguson,D.M.;Spellmeyer,D.C.;Fox, T.;Caldwell,J.W.;Kollman,P.A.J.Am.Chem.Soc.1995,117,5179–5197.22.Kirschner,K.N.;Woods,R.J.Proc.Natl.Acad.Sci.U.S.A.2001,98,10541–10545.23.Woods,R.J.;Dwek,R.A.;Edge,C.J.;Fraser-Reid,B.J.Phys.Chem.1995,99,3832–3846.24.Frisch,M.J.;Trucks,G.W.;Schlegel,H.B.;Scuseria,G.E.;Robb,M.A.;Cheeseman,J.R.;Zakrzewski,V.G.;Montgomery,J.A.,Jr.;Stratmann,R.E.;Burant,J.C.;Dapprich,S.;Millam,J.M.;Daniels,A.D.;Kudin,K.N.;Strain,M.C.;Farkas,O.;Tomasi,J.;Barone,V.;Cossi, M.;Cammi,R.;Mennucci,B.;Pomelli,C.;Adamo,C.;Clifford,S.;Ochterski,J.;Petersson,G.A.;Ayala,P.Y.;Cui,Q.;Morokuma,K.;Malick,D.K.;Rabuck,A.D.;Raghavachari,K.;Foresman,J.B.;Cioslowski,J.;Ortiz, J.V.;Stefanov,B.B.;Liu,G.;Liashenko,A.;Piskorz,P.;Komaromi,I.;Gomperts,R.;Martin,R.L.;Fox,D.J.;Keith,T.;Al-Laham,M.A.;Peng,C.Y.;Nanayakkara,A.;Gonzalez, C.;Challacombe,M.;Gill,P.M.W.;Johnson, B.;Chen,W.;Wong,M.W.;Andres,J.L.;Head-Gordon,M.;Replogle,E.S.;Pople,J.A.GAUSSIAN 98,9ed.;Gaussian,1998.25.Jorgensen,W.L.;Chandrasekhar,J.;Madura,J. D.;Impey,R.W.;Klein,M.L.J.Chem.Phys.1983,79,926–935.38S.Pedatella et al./Carbohydrate Research343(2008)31–38。
labetuzumab govitecan 结构
Labetuzumab govitecan 是一种抗体药物偶联物（ADC），由以下三个主要部分组成：
1. 抗体Labetuzumab：这是一种靶向CEACAM5（癌胚抗原相关细胞粘附分子5）的单克隆抗体。
2. SN-38：这是拓扑异构酶I抑制剂的一种活性形式，它是伊立替康（irinotecan）的一个更活跃的代谢产物。
3. pH敏感连接子：这种连接子能够在肿瘤细胞内部的低pH环境中断开，从而释放SN-38，对肿瘤细胞产生毒性作用。
Labetuzumab govitecan的作用机制包括CEACAM5拮抗剂和TOP1抑制剂的双重作用。
它通过抗体Labetuzumab特异性地结合到CEACAM5阳性的肿瘤细胞上，然后利用SN-38的强大细胞毒性来杀死这些肿瘤细胞。
总的来说，这种ADC的设计旨在提高化疗药物的靶向性，减少对正常细胞的毒副作用，从而提高治疗效果和患者的耐受性。
Labetuzumab govitecan的研发和应用是肿瘤治疗领域的一个重要进展，特别是在针对CEACAM5表达较高的肿瘤类型中。
2-Methoxyestradiol (2-MeOE2)_凋亡、抗增殖和抗血管新生的试剂_362-07-2_Apexbio
有抗增值活性，对随后的小鼠皮下接种的肿瘤生长有抑制作用。 参考文献: [1]. Takeki Tsutsui, Yukiko Tamura, Makoto Hagiwara, Takashi Miyachi, Hirohito Hikiba, Chikahiro Kubo and J. Carl Barret. Induction of mammalian cell transformation and genotoxicity by 2-methoxyestradiol, an endogenous metabolite of estrogen. Carcinogensis 2000; 21(4): 735-740 [2]. Hesham Attalla, Tomi P. Makela, Herman Adlercreutz and Leif C. Anderson. 2-Methoxyestradiol arrests cells in mitosis without depolymerizing tubulin. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 1996; 228: 467-473.
特别声明
产品仅用于研究，
不针对患者销售，望谅解。 每个产品具体的储存和使用信息显示在产品说明书中。ApexBio 产品在推荐的条件下是稳定 的。产品会根据不同的推荐温度进行运输。许多产品短期运输是稳定的，运输温度不同于长 期储存的温度。我们确保我们的产品是在保持试剂质量的条件下运输的。收到产品后，按照 产品说明书上的要求进行储存。
302.41
C19H2Байду номын сангаасO3
2-methoxy Estradiol
ML-265_肿瘤特异性PKM2激活剂_1221186-53-3_Apexbio
生物活性
靶点 :
Metabolism
信号通路:
Pyruvate kinase
参考文献: [1]. Anastasiou D, Yu Y, Israelsen WJ, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol. 2012 Oct;8(10):839-47. [2]. Walsh MJ, Brimacombe KR, Anastasiou D, et al. ML265: A potent PKM2 activator induces tetramerization and reduces tumor formation and size in a mouse xenograft model. Probe Reports from the NIH Molecular Libraries Program [Internet].
highly proliferative cells including all cancer cell lines and tumors, which require high amounts of glucose for proliferation [1][2]. ML-265 is a potent and selective PKM2 activator with AC50 value of 92 nM. ML-265 exhibits high selectivity over PKM1, PKR and PKL. ML-265 decreased the Km of PKM2 for PEP in a way similar to the endogenous activator FBP. ML-265 also increased PKM2 activity by promoting the tetrameric state [1]. In mice with A549 xenograft tumors, ML-265 exhibited good oral bioavailability with relatively low clearance, long half-life. ML-265 (150 mg/kg) readily achieved maximal PKM2 activation. In mice bearing H1299 xenograft tumors, ML-265 inhibited tumor growth, suggesting that increased pyruvate kinase activity can impair tumorigenesis [1][2].
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
体外：研究发现 AG-221 能够将 2-HG 水平降低超过 90％，逆转体外组蛋白和 DNA 超甲基化， 并诱导白血病细胞模型中的分化。此外，通过测量 CD11b、CD14、CD15 的表达和细胞形态 学，观察到 AG-221 治疗引起人特异性 CD45+胚细胞剂量依赖性的增殖爆发[1]。 体内：研究 AG-221 在具有 IDH2 R140Q 突变的原发性人 AML 异种移植物模型中的功效，结 果显示 AG-221 可有效降低移植小鼠的血浆、骨髓和尿中的 2-HG。此外，AG-221 的高剂量 治疗中所有小鼠存活至研究结束，表明 AG-221 治疗还可以诱导显著的和剂量依赖性的存活 改善[1]。 临床试验：已经在具有 IDH2 突变的晚期血液恶性肿瘤患者中进行 AG-221 的 1 期、多中心、 剂量递增、安全性、PK、PD 和临床活性研究[2]。
特别声明
产品仅用于研究，
不针对患者销售，望谅解。
每个产品具体的储存和使用信息显示在产品说明书中。ApexBio 产品在推荐的条件下是稳定 的。产品会根据不同的推荐温度进行运输。许多产品短期运输是稳定的，运输温度不同于长 期储存的温度。我们确保我们的产品是在保持试剂质量的条件下运输的。收到产品后，按照 产品说明书上的要求进行储存。
运输条件:
2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethy l)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol
CC(O)(C)CNC1=NC(C2=NC(C(F)(F)F)=CC=C2)=NC(NC3=CC(C(F)(F)F)=N C=C3)=N1
Soluble in DMSO
Store at -20°C
For obtaining a higher solubility , please warm the tube at 37°C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.
产品说明书
化学性质
产品名: Cas No.: 分子量: 分子式:
AG-221 (Enasidenib) 1446502-11-9 473.37 C19H17F6N7O
产品名: AG-221 (Enasidenib) 修订日期: 6/30/2016
化学名: SMILES: 溶解性: 储存条件: 一般建议:
ApexBio Technology
参考文献: [1] Kate Ellwood-Yen, Fang Wang, Jeremy Travins, Yue Chen, Hua Yang, Kim Straley, Sung Choe, Marion Dorsch, Sam Agresta, David Schenkein, Scott Biller, Michael Su. AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3116. doi:10.1158/1538-7445.AM2014-3116 [2] https://clinicaltrials. gov/ct2/show/NCT02577406term=Enasidenib&rank=1
Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
生物活性
靶点 :
Metabolism
信号通路:
Dehydrogenase
பைடு நூலகம்
产品描述:
作用于 IDH2 R140Q 突变体，IC50 约为 16 nM。 AG-221（Enasidenib）是突变异柠檬酸脱氢酶 2（IDH2）抑制剂。 在急性骨髓性白血病患者中发现 IDH1 和 IDH2 的体细胞突变。白血病相关的 IDH1 / 2 突变导 致代谢产物 2-羟基戊二酸（2-HG）的异常积累。